
Canary Capital's Staked INJ ETF began trading on Nasdaq, giving brokerage-account investors INJ exposure plus staking rewards in NAV. INJ is up nearly 26% since 3 Nov.
In brief
- Canary Capital's Staked Injective Protocol
INJ ETF, ticker INJC, debuted on Nasdaq and stakes most of its holdings on Injective, according to Coin Bureau. - The fund gives investors Injective Protocol
INJ exposure through a brokerage account, with staking rewards reflected in net asset value (NAV), according to The Block. - Injective
INJ has climbed nearly +26% since 3 Nov amid the listing news, Coin Bureau reported.
What happened
Canary Capital's Staked Injective Protocol
INJ ETF began trading on Nasdaq under the ticker INJC, The Block reported on 5 November.
The fund gives investors exposure to Injective's
INJ token through a brokerage account, plus staking rewards reflected in its net asset value (NAV).
Injective and Canary Capital rang the Nasdaq opening bell in Times Square a day after the debut, according to Coin Bureau.
The ETF was up +3% on the day of the bell ceremony.
Coin Bureau called INJC the first US staked Injective ETF.
It said the fund stakes most of its holdings on Injective.
Why it matters
A staked ETF ties the fund's returns to Injective's staking yield, not just the token price.
Rewards are folded into NAV rather than paid out separately, per The Block.
The listing has coincided with a sharp move in the token.
Injective Protocol
INJ has climbed nearly +26% since 3 Nov amid the listing news, Coin Bureau reported, even as the wider crypto market sold off.
Injective
INJ traded near $8.40 at 15:27 UTC, up +5.20% over 24 hours, according to Hyperliquid data.
What to watch
Whether the fund's staking of most of its holdings draws Injective Protocol
INJ into validator staking, and whether the token holds its gains after the listing news fades.